Passage Bio, Inc. Common Stock
PASGPassage Bio, Inc. is a biopharmaceutical company focused on developing gene therapies for rare and devastating neurological and genetic disorders. Established with the goal of transforming patient lives, Passage Bio leverages its proprietary platform to discover and develop treatments targeting novel genetic and neurological conditions.
Company News
The global Sandhoff disease treatment market is projected to grow from $260 million in 2024 to $456.42 million by 2034, with a 5.75% CAGR. North America dominates the market, and gene therapy is expected to be a key growth segment for treating this rare genetic disorder.
The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safet...
Passage Bio, a clinical-stage genetic medicines company, announced that it will participate in upcoming investor conferences, including the TD Cowen 45th Annual Health Care Conference and the Leerink Global Biopharma Conference.
Passage Bio, a clinical-stage genetic medicines company, announced that its president and CEO will present at the Guggenheim Securities Healthcare Innovation Conference on November 13, 2024. The company is focused on developing one-time therapies for neurodegenerative diseases, with its lead product candidate PBFT02 targeting frontotemporal demen...
Passage Bio, a clinical-stage genetic medicines company, announced that its president and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024.
